David Leung
Head, Imaging Daiichi Sankyo
David is a dual board-certified radiologist and nuclear medicine physician. He joined Daiichi Sankyo as Head of Imaging in 2023. Previously, he led translational medicine at RefleXion Medical and headed oncology imaging at Bristol-Myers Squibb, where he oversaw development of novel PET tracers and imaging biomarkers in clinical trials. Earlier in his career, David was an radiologist and modality chief of nuclear medicine at Columbia University in New York, where he also earned his MD and PhD in chemistry. His research dedicated to advancing imaging biomarkers and PET tracers to improve outcome in oncology and other therapeutic areas.
Seminars
Wednesday 25th February 2026
Evaluating Intracranial Response with DXd ADCs & Other Biologics: Lessons Learned & Opportunities Ahead
11:30 am
- Traditionally, large molecules including ADCs are thought to have no intracranial efficacy due to inability to cross the blood brain barrier
- Presenting evidence of intracranial efficacy of multiple DXd ADCs and mAbs, challenging this dogma
- Explaining this information can be utilised to address the unmet needs for patients with brain metastases
